Ekaterina (Kate) Dadachova, PhD, joined University of Saskatchewan in Canada late in 2016 as a Fedoruk Center for Nuclear Innovation Chair in Radiopharmacy, and a Professor of Pharmacy.
 

Before joining University of Saskatchewan, she held a Professorship in Radiology, Microbiology and Immunology at the Albert Einstein College of Medicine in New York, USA from 2000 to 2016.

Her research interests are radioligand therapy of cancer, infections and autoimmune diseases, as well as interaction of melanized fungi with ionizing radiation and melanin-based radioprotectors.
 

She published more than 210 papers, 13 book chapters, and has 8 US patents. She received several awards such as Philips Young Investigator Award by RSNA, Young Professionals Award from the SNM, Mary Kay Ash Research Award, Top 10 researchers at the Albert Einstein College of Medicine in 2013, 2017 Burroughs Welcome Award, 2020 University of Saskatchewan Distinguished Researcher Award and 2024 Saskatchewan Health Research Foundation (SHRF) Years of Service Award. She is in the top 2% of cited scientists worldwide according to Stanford University 2024 database.
 

Prof Dr Ekaterina Dadachova, PhD

• Professor, College of Pharmacy and Nutrition
  & Editor in Chief, Cancer Biotherapy and Radiopharmaceuticals
• Sylvia Fedoruk Center for Nuclear Innovation Chair in Radiopharmacy University of Saskatchewan, Canada

• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Rudi Dierckx highlights the key industry challenges and opportunities in nuclear medicine.

• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Dierckx explores the research that is opening new perspectives across all therapeutic areas.

• Past President of European Association of Nuclear Medicine (2023 - 2024)

Prof Dr Rudi Dierckx navigates through the evolving landscape of nuclear medicine, from the significant advancements to the growing interest of pharmaceutical industry.

V. Bonvin^{a ,b, *}, F. Bochud^b, J. Damet ^b,d , C. Theis^a, H. Vincke^a,c, R. Geyer^a,b
aEuropean Council for Nuclear Research (CERN), Esplanade des Particules, CH-1211, Meyrin, Switzerland
^bInstitute for Radiation Physics, Lausanne University Hospital, Rue du Grand-Pr´ e, CH-1007, Lausanne, Switzerland
^cUniversity of Technology, Rechbauerstraße 12, 8010, Graz, Austria
^dUniversity of Otago, 2 Riccarton Ave, Christchurch, New Zealand   

C. Gameiro¹, V. H. Alves², A. Abrunhosa³, F. Alves², D. Goblet¹, B. Nactergal¹, A. Uhlending³, V. Hugenberg³, T. Ortgies³, G. Hoeger³, J. Manrique-Arias⁴, R. Freifelder⁵, K. Hye-Yeong⁵, M. Bhuiyan⁵,  A. Kucharski^5 
1IBA, Louvain-La-Neuve, BELGIUM,
²Institute for Nuclear Sciences Applied in Health (ICNAS), Coimbra, PORTUGAL,
³Department of Radiology, Nuclear medicine and Molecular Imaging, Bad Oeynhausen, GERMANY,
⁴Cyclotron Department, Doctors Hospital, Monterrey, MEXICO,
⁵Department of Radiology, University of Chicago, Chicago, IL, US.

IBA RadioPharma Solutions & IBA Customer Service, Louvain-la-Neuve, Belgium
Cyclotron Research Center, University of Liège, Belgium- link 

Nicholas P. van der Meulen^1,2,*, Roger Hasler², Chiara Favaretto ², Zeynep Talip ², Pascal V. Grundler ², Christoph A. Umbricht ², Cristina Müller ², Tommaso S. Carzaniga ³  and Saverio Braccini ³, Gaia Dellepiane ^3
1Laboratory of Radiochemistry, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland
²Center of Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, 5232 Villigen-PSI, Switzerland; rogerhasler26@gmail.com (R.H.); zeynep.talip@psi.ch (Z.T.); pascal.grundler@psi.ch (P.V.G.); chiara.favaretto@psi.ch (C.F.); christoph.umbricht@gmail.com (C.A.U.); Cristina.mueller@psi.ch (C.M.) 
³Albert Einstein Center for Fundamental Physics, Laboratory of High Energy Physics, University of Bern, 3012 Bern, Switzerland; gaia.dellepiane@lhep.unibe.ch (G.D.); tommaso.carzaniga@lhep.unibe.ch (T.S.C.); saverio.braccini@lhep.unibe.ch (S.B.) 
^*Correspondence: nick.vandermeulen@psi.ch

Christopher Marshall , Adam Dabkowski , Matthew Talboys , Sophie Wiltshire , Ken Buckley , Stuart McDiarmid , Victoire Hanemaayer , Stefan Zeisler , Paul Schaffer , Fabienne Devillet and Delphine Blampain

Objective(s): The aim of this research was the development of ¹¹¹In‐labeled porphyrins as possible radiopharmaceuticals for the imaging of tumors.            

Shaghayegh Sadeghi, Mohammad Mirzaei, Mohammad Rahimi, Amir R. Jalilian